Behavioral Symptoms  >>  bupropion sustained-release  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bupropion sustained-release / Generic mfg.
NCT01138007: A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

Completed
3
572
Japan, RoW
323U66 SR 150 mg tablet, 323U66 SR 150 mg placebo tablet
GlaxoSmithKline
Depressive Disorder, Major
08/12
08/12
VAST-D, NCT01421342: VA Augmentation and Switching Treatments for Improving Depression Outcomes

Completed
3
1522
US
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
VA Office of Research and Development
Major Depressive Disorder
08/15
06/16

Download Options